Aberrant TGF-beta production and regulation in metastatic malignancy - PubMed (original) (raw)

Aberrant TGF-beta production and regulation in metastatic malignancy

L C Schwarz et al. Growth Factors. 1990.

Abstract

We have examined the possible role of transforming growth factor-beta (TGF-beta) in metastatic malignancy by analyzing the production and activation of TGF-beta 1 and -beta 2 and the regulation of TGF-beta-responsive genes in oncogene-transformed metastatic fibrosarcomas. All transformed lines derived from either 10T1/2 or NIH 3T3 by either H-ras or protein-kinase encoding oncogenes produced more TGF-beta than parental cells. However, only highly metastatic fibrosarcomas secreted activated TGF-beta at rates that were greater than parental fibroblasts. Immunohistochemical staining for TGF-beta 1 showed widespread intra- and extracellular distribution in metastatic lung nodules and adjacent tissue. Cells isolated from tumors successfully metastasizing to the lung had TGF-beta 1 mRNA levels which were increased 19-fold over in vitro controls. Despite the greatly enhanced rate of secretion of activated TGF-beta, metastatic cells exhibited markedly altered responses of TGF-beta 1 and TGF-beta 2, being unable to either increase collagen secretion or enhance collagen alpha 2(1) or TGF-beta 1 mRNA levels. This lack of response was not due to either altered TGF-beta receptor affinity or numbers. Metastatic progression was, therefore, associated with an increase in the secretion of activated TGF-beta 1 and a loss of the ability to deregulate TGF-beta-responsive genes.

PubMed Disclaimer

Similar articles

• Transforming growth factor beta 1 selectively regulates ornithine decarboxylase gene expression in malignant H-ras transformed fibrosarcoma cell lines.
  Hurta RA, Greenberg AH, Wright JA. Hurta RA, et al. J Cell Physiol. 1993 Aug;156(2):272-9. doi: 10.1002/jcp.1041560208. J Cell Physiol. 1993. PMID: 8344985
• Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-beta 1.
  Beauchamp RD, Sheng HM, Bascom CC, Miller DA, Lyons RM, Torre-Amione G, Moses HL. Beauchamp RD, et al. Endocrinology. 1992 May;130(5):2476-86. doi: 10.1210/endo.130.5.1374006. Endocrinology. 1992. PMID: 1374006
• Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7.
  Dubinett SM, Huang M, Dhanani S, Economou JS, Wang J, Lee P, Sharma S, Dougherty GJ, McBride WH. Dubinett SM, et al. J Natl Cancer Inst. 1995 Apr 19;87(8):593-7. doi: 10.1093/jnci/87.8.593. J Natl Cancer Inst. 1995. PMID: 7752257
• Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
  Kang Y, Mariano JM, Angdisen J, Moody TW, Diwan BA, Wakefield LM, Jakowlew SB. Kang Y, et al. Mol Carcinog. 2000 Oct;29(2):112-26. doi: 10.1002/1098-2744(200010)29:2<112::aid-mc8>3.0.co;2-9. Mol Carcinog. 2000. PMID: 11074608
• Overexpression of c-K-ras, c-N-ras and transforming growth factor beta co-segregate with tumorigenicity in morphologically transformed C3H 10T1/2 cell lines.
  Coleman WB, Throneburg DB, Grisham JW, Smith GJ. Coleman WB, et al. Carcinogenesis. 1994 May;15(5):1005-12. doi: 10.1093/carcin/15.5.1005. Carcinogenesis. 1994. PMID: 8200061

Cited by

• Transforming growth factor beta and the cell surface in tumor progression.
  Newman MJ. Newman MJ. Cancer Metastasis Rev. 1993 Sep;12(3-4):239-54. doi: 10.1007/BF00665956. Cancer Metastasis Rev. 1993. PMID: 8281611 Review.
• Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice.
  Hoefer M, Anderer FA. Hoefer M, et al. Cancer Immunol Immunother. 1995 Nov;41(5):302-8. doi: 10.1007/BF01517218. Cancer Immunol Immunother. 1995. PMID: 8536276 Free PMC article.
• Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells.
  Bartlett JM, Rabiasz GJ, Scott WN, Langdon SP, Smyth JF, Miller WR. Bartlett JM, et al. Br J Cancer. 1992 May;65(5):655-60. doi: 10.1038/bjc.1992.140. Br J Cancer. 1992. PMID: 1586592 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal